Evidence map›Paper›PMID 39873852›Full record

SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

Methodologies and characteristics of studies investigating the cost of the palliative phase of cancer: a systematic review.

Kevin Chechirlian, Maxime Messin, Raphaelle Habert Dantigny, Guillaume Economos, Caroline Tête, Elise Perceau-Chambard, Fiona Ecarnot, Eduardo Bruera, Stéphane Sanchez, Cecile Barbaret

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kevin ChechirlianDepartment of Supportive and Palliative Care, Centre Hospitalo-Universitaire de Grenoble, Grenoble, France.
Maxime MessinDepartment of Supportive and Palliative Care, Centre Hospitalo-Universitaire de Grenoble, Grenoble, France.
Raphaelle Habert DantignyDepartment of Supportive and Palliative Care, Centre Hospitalo-Universitaire de Grenoble, Grenoble, France.
Guillaume EconomosEA3738-Centre Pour L'Innovation en Cancérologie de Lyon, UFR Faculté de Médecin Lyon-Sud, Université Claude Bernard Lyon 1, Oullins, France.
Caroline TêteUniv. Grenoble Alpes, CNRS, CHU Grenoble Alpes, Grenoble INP*, TIMC-IMAG, Institute of Engineering Univ. Grenoble Alpes, 38000, Grenoble, France.
Elise Perceau-ChambardEA3738-Centre Pour L'Innovation en Cancérologie de Lyon, UFR Faculté de Médecin Lyon-Sud, Université Claude Bernard Lyon 1, Oullins, France.
Fiona EcarnotDepartment of Cardiology, Centre Hospitalo-Universitaire de Besancon, Besancon, France.
Eduardo BrueraDepartment of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stéphane SanchezDepartment of Public Health, Hospital Champagne Sud, Troyes, France.
Cecile BarbaretDepartment of Supportive and Palliative Care, Centre Hospitalo-Universitaire de Grenoble, Grenoble, France. cbarbaret@chu-grenoble.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeImprovements in the treatment of advanced cancer have increased life expectancy but have also increased the costs to healthcare systems, patients and their families. A systematic review is needed to summarize research work on the cost of cancer. The primary objective was to describe the characteristics and methodology of studies investigating the cost of cancer during the palliative phase. Secondary objectives were to assess whether palliative care interventions influence the costs of advanced cancer and to describe the costs explored and models used in cost-effectiveness studies.

methodAccording to the PRISMA guideline (Preferred Reporting Items for Systematic Reviews and Meta-Analyses), Pubmed, Web of Science, NHS, EconLit and Google Scholar databases were screened from 11/01/2020 to 03/01/2024. All types of methods about the costs of the palliative phase of solid cancer were accepted. Study characteristics, economic perspective, time horizon and the type of costs explored were collected.

resultsOf the 498 studies identified, 66 were included in the final analysis. Most (60%) used a retrospective methodology. Almost all (65, 98%) studied direct costs, and only 12 (18%) studied indirect costs. No article assessed intangible costs or the total cost of the palliative phase of cancer. The payer's perspective was most commonly adopted (39, 59%). The time horizon was less than 6 months in most cases (41, 63%). Eighteen studies (86%) highlighted that PC interventions were cost-effective.

conclusionExisting evidence suggests that palliative care is cost-effective from the hospital and payer's perspective. More research is needed to evaluate the cost of informal caregiving and out-of-pocket expenses borne by patients.

Indexed as

Cost of IllnessHealth Care CostsNeoplasmsPalliative CareCost-Benefit AnalysisCost-Effectiveness AnalysisHumansCancerCharacteristicsCostsDirect costIndirect costIntangible costMethodologiesPalliative careSystematic review

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.